Quan Vu Biography and Net Worth



Quan Vu brings more than 20 years of “hands-on” healthcare business executive experience with an emphasis on corporate & business development, strategy, finance and operations. He possesses a demonstrated history of prospecting, evaluating, structuring and closing transactions that augment both organizational and shareholder value. He’s also a strategist with a sound understanding of pipeline development, commercial assessment and go-to-market strategies. An adept finance professional, Quan has consummated billions of dollars in capital raises and M&A deals for public and private companies. He’s also an operator proficient at navigating complex situations, identifying improvement opportunities and propelling enterprise-wide changes to optimize performance.

In the past two years prior to joining 180 Life Sciences, Quan held several concurrent leadership roles. He served as the CEO of Baleena Bioscience, a consolidator of several healthspan biotechnology/medical device assets with the express purpose of going public via a SPAC. Additionally, he served as a Managing Director and Co-Head of Healthcare IT for Solganick & Co., a boutique technology investment bank providing M&A advisory. He also provided interim CFO/CBO consulting services, including private capital raises and out-licensing, as a member of LS Associates, a division of LifeSci Partners.

Before his roles above, Quan served as Vice President of Strategy & Corporate/Business Development at Opiant Pharmaceuticals, a public company focused on addiction and drug overdose, where he directly facilitated the company’s growth from 3 to 16 FTEs and from $10M to $60M market capitalization in under three years. Prior to Opiant, he served as a Staff Vice President at Anthem with responsibilities for strategy, planning and administration, including the management of a $2.2B IT budget. Prior to Anthem, he held leadership roles at Impax Laboratories and Amgen as a Director and Senior Manager, respectively, with responsibilities that encompassed strategy, corporate/business development and finance.

Quan began his career in financial and economic consulting at LECG and in healthcare corporate finance and M&A at bulge-bracket investment banks, including Morgan Stanley and Goldman Sachs. He obtained his BA in Economics from UCLA, graduating summa cum laude with College Honors and Economics Departmental Honors. He is also a Certified Treasury Professional (inactive).

How do I contact Quan Anh Vu?

The corporate mailing address for Mr. Vu and other 180 Life Sciences executives is 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007. 180 Life Sciences can also be reached via phone at (650) 507-0669 and via email at [email protected]. Learn More on Quan Anh Vu's contact information.

Has Quan Anh Vu been buying or selling shares of 180 Life Sciences?

Quan Anh Vu has not been actively trading shares of 180 Life Sciences over the course of the past ninety days. Most recently, on Thursday, December 16th, Quan Anh Vu bought 21 shares of 180 Life Sciences stock. The stock was acquired at an average cost of $1,512.40 per share, with a total value of $31,760.40. Learn More on Quan Anh Vu's trading history.

Who are 180 Life Sciences' active insiders?

180 Life Sciences' insider roster includes Donald McGovern, Jr. (Director), Ozan Pamir (CFO), Quan Vu (COO), and James Woody (CEO). Learn More on 180 Life Sciences' active insiders.

Quan Anh Vu Insider Trading History at 180 Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2021Buy21$1,512.40$31,760.40View SEC Filing Icon  
12/10/2021Buy11$1,482.00$16,302.00View SEC Filing Icon  
See Full Table

Quan Anh Vu Buying and Selling Activity at 180 Life Sciences

This chart shows Quan Anh Vu's buying and selling at 180 Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

180 Life Sciences Company Overview

180 Life Sciences logo
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $2.37
Low: $2.25
High: $2.49

50 Day Range

MA: $2.66
Low: $1.18
High: $6.47

2 Week Range

Now: $2.37
Low: $1.16
High: $17.75

Volume

41,272 shs

Average Volume

795,365 shs

Market Capitalization

$2.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23